Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Multi-Omics Analysis of Proteasome Inhibitor Resistance in Multiple Myeloma

Seungbin Han, Chien-Yun Lee, Lenka Besse, Umair Munawar, Andrej Besse, Ann-Sohpie Hainold, Silvia Nerreter, Cornelia Vogt, Shilpa Kurian, Xiang Zhou, Larissa Haertle, Johannes Waldschmidt, Christoph Driessen, Hermann Einsele, Leo Rasche, Bernhard Kuster, K. Martin Kortüm

Blood (2024) 144 (Supplement 1): 6817.

https://doi.org/10.1182/blood-2024-203352

Published: 2024

Journal Articles

Regulation of BCMA By the Ubiquitin Proteasome System Enables Optimization of BCMA-Targeting Therapies in Multiple Myeloma

Leonie Rieger, Kilian Irlinger, Franziska Fuechsl, Nicolas Barbian, Marlene Tietje, Melanie Faber, Tobias Schulze, Piero Giansanti, Lenka Besse, Christoph Driessen, Angela Krackhardt, Bernhard Kuster, Florian Bassermann

Blood (2023) 142 (Supplement 1): 3310.

https://doi.org/10.1182/blood-2023-187349

Published: 2023

Journal Articles

Targeting IGF1R/Insr Pathway with Approved ALK-Inhibitors Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma

Max Alberto Mendez-Lopez, Andrej Besse, Tiberiu Totu, Marianne Kraus, Anthonius P.A. Janssen, Marija Buljan, Mario Van Der Stelt, Lenka Besse, Christoph Driessen

Blood (2023) 142 (Supplement 1): 4663.

https://doi.org/10.1182/blood-2023-177912

Published: 2023

Journal Articles

Impact of ABCB1 Promoter Methylation on PI-Resistance in Multiple Myeloma

Blood (2022) 140 (Supplement 1): 12462–12463.

https://doi.org/10.1182/blood-2022-168694

Published: 2022

Journal Articles

Bortezomib Resistant Multiple Myeloma Shows a Specific Dependency on Ecpas in Vitro and In Vivo

Lenka Besse, Andrej Besse, Sara C. Stolze, Amin Sobh, Marianne Kraus, Hirofumi Nakagami, Christoph Driessen

Blood (2022) 140 (Supplement 1): 4183–4184.

https://doi.org/10.1182/blood-2022-167648

Published: 2022

Journal Articles

The Molecular Landscape and Essential Pathways Involved in Bone Marrow-Mediated Carfilzomib Resistance of Multiple Myeloma

Jonas Schwestermann, Andrej Besse, Serena Fazio, Cesar Nombela-Arrieta, Lenka Besse, Christoph Driessen

Blood (2022) 140 (Supplement 1): 4228–4229.

https://doi.org/10.1182/blood-2022-169024

Published: 2022

Journal Articles

Blocking the Don't Eat Me Signal (CD47-SIRPα Axis) to Improve Antibody-Based Immunotherapy of Multiple Myeloma

Katja Klausz, Carina Lynn Gehlert, Ammelie Svea Boje, Marta Lustig, Steffen Krohn, Syeda Maliha Ahmed, Christian Kellner, Thomas Valerius, Lenka Besse, Andrej Besse, Christoph Driessen, Martin Gramatzki, Matthias Peipp

Blood (2021) 138 (Supplement 1): 2684.

https://doi.org/10.1182/blood-2021-152208

Published: 2021

Journal Articles

High-Dose Carfilzomib Recaptures Response in Relapsed/Refractory Multiple Myeloma Resistant to Low-Dose Carfilzomib By Co-Inhibiting β2 Subunit of Proteasome Complex: The First in Human Evidence

Xiang Zhou, Andrej Besse, Jessica Peter, Max Mendez Lopez, Larissa Haertle, Umair Munawar, Seungbin Han, Elmer Maurits, Herman S. Overkleeft, Hermann Einsele, Christoph Driessen, Martin Kortuem, Lenka Besse, Leo Rasche

Blood (2021) 138 (Supplement 1): 818.

https://doi.org/10.1182/blood-2021-147170

Published: 2021

Journal Articles

Essential Drug Targets and Pathways in PI-Resistant MM Cells

Andrej Besse, Lenka Besse, Lorina Büchler, Sara C. Stolze, Amin Sobh, Marianne Kraus, Hirofumi Nakagami, Christoph Driessen

Blood (2021) 138 (Supplement 1): 1577.

https://doi.org/10.1182/blood-2021-150117

Published: 2021

Journal Articles

The Molecular Landscape and Essential Pathways Involved in Bone Marrow-Mediated Carfilzomib Resistance of Multiple Myeloma

Jonas Schwestermann, Andrej Besse, Lenka Besse, Christoph Driessen

Blood (2021) 138 (Supplement 1): 1571.

https://doi.org/10.1182/blood-2021-148395

Published: 2021

Journal Articles

All-Trans-Retinoic Acid Prevents Carfilzomib-Induced Cardiotoxicity By Decreasing Activation of the Renin-Angiotensin System

Max A Mendez, Andrej Besse, Bogdan I. Florea, Christian Zuppinger, Herman S. Overkleeft, Lenka Besse, Christoph Driessen, MD

Blood (2020) 136 (Supplement 1): 19–20.

https://doi.org/10.1182/blood-2020-139277

Published: 2020

Journal Articles

Effect of ABCB1 Multidrug Resistance Protein on Efficacy of Anti-Myeloma Drugs in Carfilzomib-Resistant Myeloma Model

Konstantin Byrgazov, PhD, Marianne Kraus, Andrej Besse, Ana Slipicevic, Fredrik Lehmann, Christoph Driessen, MD, Lenka Besse

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-136725

Published: 2020

Journal Articles

Nelfinavir Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma By Modulating Membrane Lipid Bilayer Composition and Fluidity

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-136253

Published: 2020

Journal Articles

Carfilzomib Induces Cardiotoxicity Via ß5/ß2-Specific Proteasome Subunit Inhibition Pattern

Max A Mendez-Lopez, MD, Andrej Besse, PhD, Bogdan Florea, PhD, Christian Zuppinger, PhD, Herman Overkleeft, PhD, Christoph Driessen, MD, Lenka Besse, PhD

Blood (2019) 134 (Supplement_1): 3110.

https://doi.org/10.1182/blood-2019-127987

Published: 2019

Journal Articles

Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modelling of Genomics and Proteomics

Andrej Besse, M.Sc, Christopher R. Cogle, MD, Leylah M. Drusbosky, PhD, Shireen Vali, PhD, Taher Abbasi, MS, MBA, Neeraj Kumar Singh, B.Tech, Neha G Gupta, M.Sc., Abha Kushwaha, M.Sc., Pallavi Kumari, M.Sc., Karthik Sundara Raju, M.Sc., Ganesh Naga, B.Tech, Sayani Basu, M.Tech, Christoph Driessen, MD, Lenka Besse, PhD

Blood (2018) 132 (Supplement 1): 3193.

https://doi.org/10.1182/blood-2018-99-116939

Published: 2018

Journal Articles

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma

Christoph Driessen, Rouven Müller, Urban Novak, Nathan Cantoni, Daniel Betticher, Nicolas Mach, Axel Rüfer, Ulrich Mey, Panagiotis Samaras, Karin Ribi, Lenka Besse, Andrej Besse, Catherine Berset, Stephanie Rondeau, Hanne Hawle, Felicitas Hitz, Thomas Pabst, Thilo Zander

Blood (2018) 132 (19): 2097–2100.

https://doi.org/10.1182/blood-2018-05-851170

Published: 2018

Includes: Supplemental data

Journal Articles

High Glutathione and NAD(P)H Levels, and Increased Protein Folding Capacity Are Involved in Mediating Proteasome Inhibitor-Resistance in Multiple Myeloma

Lenka Besse, Andrej Besse, Marianne Kraus, Jürgen Bader, Christoph Driessen, MD

Blood (2017) 130 (Supplement 1): 1258.

https://doi.org/10.1182/blood.V130.Suppl_1.1258.1258

Published: 2017

Journal Articles

Defining the Most Effective Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors

Andrej Besse, Lenka Besse, Marianne Kraus, Juergen Bader, Gerjan de Bruin, Herman S Overkleeft, Christoph Driessen, MD

Blood (2017) 130 (Supplement 1): 5388.

https://doi.org/10.1182/blood.V130.Suppl_1.5388.5388

Published: 2017

Journal Articles

Nelfinavir and Lenalidomide/Dexamethasone in Patients with Lenalidomide-Refractory Multiple Myeloma. A Phase I/II Trial — SAKK 39/10

Felicitas - Hitz, MD, Thomas - Pabst, MD, Dagmar - Hess, MD, Marianne Kraus, Lenka Besse, Urban Novak, MD, Katja - Seipel, MD, Stephanie - Rondeau, Silvia - Stüdeli, Simona Berardi, MD, Samaras Panagiotis, MD, Ulrich Mey, MD, Christoph Driessen, MD

Blood (2017) 130 (Supplement 1): 1884.

https://doi.org/10.1182/blood.V130.Suppl_1.1884.1884

Published: 2017

Journal Articles

Nelfinavir Blocks Export of Newly Synthesized Protein from the ER and Interacts with ER-Resident and Mitochondrial Proteins in an Activity-Dependent Fashion

Andrej Besse, Lenka Besse, Sara C. Stolze, Marianne Kraus, Juergen Bader, Herman S Overkleeft, Christoph Driessen, MD

Blood (2017) 130 (Supplement 1): 3074.

https://doi.org/10.1182/blood.V130.Suppl_1.3074.3074

Published: 2017

NARROW

Multi-Omics Analysis of Proteasome Inhibitor Resistance in Multiple Myeloma

Regulation of BCMA By the Ubiquitin Proteasome System Enables Optimization of BCMA-Targeting Therapies in Multiple Myeloma

Targeting IGF1R/Insr Pathway with Approved ALK-Inhibitors Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma

Impact of ABCB1 Promoter Methylation on PI-Resistance in Multiple Myeloma

Bortezomib Resistant Multiple Myeloma Shows a Specific Dependency on Ecpas in Vitro and In Vivo

The Molecular Landscape and Essential Pathways Involved in Bone Marrow-Mediated Carfilzomib Resistance of Multiple Myeloma

Blocking the Don't Eat Me Signal (CD47-SIRPα Axis) to Improve Antibody-Based Immunotherapy of Multiple Myeloma

High-Dose Carfilzomib Recaptures Response in Relapsed/Refractory Multiple Myeloma Resistant to Low-Dose Carfilzomib By Co-Inhibiting β2 Subunit of Proteasome Complex: The First in Human Evidence

Essential Drug Targets and Pathways in PI-Resistant MM Cells

The Molecular Landscape and Essential Pathways Involved in Bone Marrow-Mediated Carfilzomib Resistance of Multiple Myeloma

All-Trans-Retinoic Acid Prevents Carfilzomib-Induced Cardiotoxicity By Decreasing Activation of the Renin-Angiotensin System

Effect of ABCB1 Multidrug Resistance Protein on Efficacy of Anti-Myeloma Drugs in Carfilzomib-Resistant Myeloma Model

Nelfinavir Overcomes Proteasome Inhibitor Resistance in Multiple Myeloma By Modulating Membrane Lipid Bilayer Composition and Fluidity

Carfilzomib Induces Cardiotoxicity Via ß5/ß2-Specific Proteasome Subunit Inhibition Pattern

Predicting Carfilzomib Resistance Mechanisms and Therapeutics Using Computational Modelling of Genomics and Proteomics

Promising activity of nelfinavir-bortezomib-dexamethasone in proteasome inhibitor–refractory multiple myeloma

High Glutathione and NAD(P)H Levels, and Increased Protein Folding Capacity Are Involved in Mediating Proteasome Inhibitor-Resistance in Multiple Myeloma

Defining the Most Effective Proteasome Inhibition in Multiple Myeloma: Head-to-Head Comparison of Currently Available Proteasome Inhibitors

Nelfinavir and Lenalidomide/Dexamethasone in Patients with Lenalidomide-Refractory Multiple Myeloma. A Phase I/II Trial — SAKK 39/10

Nelfinavir Blocks Export of Newly Synthesized Protein from the ER and Interacts with ER-Resident and Mitochondrial Proteins in an Activity-Dependent Fashion

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only